Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia

Mette Levinsen; Diana Shabaneh; Cathrine Bohnstedt; Arja Harila-Saari; Olafur G Jonsson; Jukka Kanerva; Anna Lindblom; Bendik Lund; Louise Elisabeth Andersen; Kjeld Schmiegelow; Nordic Society of Paediatric Haematology and Oncology (NOPHO)

doi:10.1111/j.1600-0609.2011.01695.x

Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia

Mette Levinsen, Diana Shabaneh, Cathrine Bohnstedt, Arja Harila-Saari, Olafur G Jonsson, Jukka Kanerva, Anna Lindblom, Bendik Lund, Louise Elisabeth Andersen, Kjeld Schmiegelow, Nordic Society of Paediatric Haematology and Oncology (NOPHO)

Afdeling for Børn og Unge JMC

22 Citationer (Scopus)

Abstract

Trimethoprim-sulfamethoxazole (TMP/SMX) is used in children with acute lymphoblastic leukemia (ALL) to prevent Pneumocystis pneumonia (PCP). We explored to which extent TMP/SMX influenced methotrexate (MTX)/6-mercaptopurine (6MP) dosage, myelosuppression, and event-free survival (EFS) during maintenance therapy. Of 447 study patients treated by the NOPHO ALL92 protocol, 120 patients received TMP/SMX continuously for 2-7 d/wk (TMP/SMX(2-7) ) and 287 patients never received TMP/SMX (TMP/SMX(never) ). Ten patients (all TMP/SMX(never) ) developed PCP, eight of which occurred within 7 months from the start of maintenance therapy. The TMP/SMX(2-7) group received lower oral 6MP doses than TMP/SMX(never) patients (50.6 vs. 63.9 mg/m(2) /d; P

Originalsprog	Engelsk
Tidsskrift	European Journal of Haematology
Vol/bind	88
Udgave nummer	1
Sider (fra-til)	78-86
Antal sider	9
ISSN	0902-4441
DOI	https://doi.org/10.1111/j.1600-0609.2011.01695.x
Status	Udgivet - 2012

Adgang til dokumentet

10.1111/j.1600-0609.2011.01695.x

Andre filer og links

Link to publication in Scopus

Citationsformater

Levinsen, M., Shabaneh, D., Bohnstedt, C., Harila-Saari, A., Jonsson, O. G., Kanerva, J., Lindblom, A., Lund, B., Andersen, L. E., Schmiegelow, K., & Nordic Society of Paediatric Haematology and Oncology (NOPHO) (2012). Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia. European Journal of Haematology, 88(1), 78-86. https://doi.org/10.1111/j.1600-0609.2011.01695.x

Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia. / Levinsen, Mette; Shabaneh, Diana; Bohnstedt, Cathrine et al.
I: European Journal of Haematology, Bind 88, Nr. 1, 2012, s. 78-86.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Levinsen, M, Shabaneh, D, Bohnstedt, C, Harila-Saari, A, Jonsson, OG, Kanerva, J, Lindblom, A, Lund, B, Andersen, LE, Schmiegelow, K & Nordic Society of Paediatric Haematology and Oncology (NOPHO) 2012, 'Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia', European Journal of Haematology, bind 88, nr. 1, s. 78-86. https://doi.org/10.1111/j.1600-0609.2011.01695.x

@article{082dec34015c4ae88fb8921345ca0185,

title = "Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia",

abstract = "Trimethoprim-sulfamethoxazole (TMP/SMX) is used in children with acute lymphoblastic leukemia (ALL) to prevent Pneumocystis pneumonia (PCP). We explored to which extent TMP/SMX influenced methotrexate (MTX)/6-mercaptopurine (6MP) dosage, myelosuppression, and event-free survival (EFS) during maintenance therapy. Of 447 study patients treated by the NOPHO ALL92 protocol, 120 patients received TMP/SMX continuously for 2-7 d/wk (TMP/SMX(2-7) ) and 287 patients never received TMP/SMX (TMP/SMX(never) ). Ten patients (all TMP/SMX(never) ) developed PCP, eight of which occurred within 7 months from the start of maintenance therapy. The TMP/SMX(2-7) group received lower oral 6MP doses than TMP/SMX(never) patients (50.6 vs. 63.9 mg/m(2) /d; P",

keywords = "6-Mercaptopurine, Administration, Oral, Anti-Infective Agents, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Male, Methotrexate, Pneumocystis jirovecii, Pneumonia, Pneumocystis, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Trimethoprim-Sulfamethoxazole Combination",

author = "Mette Levinsen and Diana Shabaneh and Cathrine Bohnstedt and Arja Harila-Saari and Jonsson, \{Olafur G\} and Jukka Kanerva and Anna Lindblom and Bendik Lund and Andersen, \{Louise Elisabeth\} and Kjeld Schmiegelow and \{Nordic Society of Paediatric Haematology and Oncology (NOPHO)\}",

note = "{\textcopyright} 2011 John Wiley \& Sons A/S.",

year = "2012",

doi = "10.1111/j.1600-0609.2011.01695.x",

language = "English",

volume = "88",

pages = "78--86",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia

AU - Levinsen, Mette

AU - Shabaneh, Diana

AU - Bohnstedt, Cathrine

AU - Harila-Saari, Arja

AU - Jonsson, Olafur G

AU - Kanerva, Jukka

AU - Lindblom, Anna

AU - Lund, Bendik

AU - Andersen, Louise Elisabeth

AU - Schmiegelow, Kjeld

AU - Nordic Society of Paediatric Haematology and Oncology (NOPHO)

PY - 2012

Y1 - 2012

N2 - Trimethoprim-sulfamethoxazole (TMP/SMX) is used in children with acute lymphoblastic leukemia (ALL) to prevent Pneumocystis pneumonia (PCP). We explored to which extent TMP/SMX influenced methotrexate (MTX)/6-mercaptopurine (6MP) dosage, myelosuppression, and event-free survival (EFS) during maintenance therapy. Of 447 study patients treated by the NOPHO ALL92 protocol, 120 patients received TMP/SMX continuously for 2-7 d/wk (TMP/SMX(2-7) ) and 287 patients never received TMP/SMX (TMP/SMX(never) ). Ten patients (all TMP/SMX(never) ) developed PCP, eight of which occurred within 7 months from the start of maintenance therapy. The TMP/SMX(2-7) group received lower oral 6MP doses than TMP/SMX(never) patients (50.6 vs. 63.9 mg/m(2) /d; P

AB - Trimethoprim-sulfamethoxazole (TMP/SMX) is used in children with acute lymphoblastic leukemia (ALL) to prevent Pneumocystis pneumonia (PCP). We explored to which extent TMP/SMX influenced methotrexate (MTX)/6-mercaptopurine (6MP) dosage, myelosuppression, and event-free survival (EFS) during maintenance therapy. Of 447 study patients treated by the NOPHO ALL92 protocol, 120 patients received TMP/SMX continuously for 2-7 d/wk (TMP/SMX(2-7) ) and 287 patients never received TMP/SMX (TMP/SMX(never) ). Ten patients (all TMP/SMX(never) ) developed PCP, eight of which occurred within 7 months from the start of maintenance therapy. The TMP/SMX(2-7) group received lower oral 6MP doses than TMP/SMX(never) patients (50.6 vs. 63.9 mg/m(2) /d; P

KW - 6-Mercaptopurine

KW - Administration, Oral

KW - Anti-Infective Agents

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Child

KW - Child, Preschool

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Male

KW - Methotrexate

KW - Pneumocystis jirovecii

KW - Pneumonia, Pneumocystis

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Trimethoprim-Sulfamethoxazole Combination

UR - https://www.scopus.com/pages/publications/83655167233

U2 - 10.1111/j.1600-0609.2011.01695.x

DO - 10.1111/j.1600-0609.2011.01695.x

M3 - Journal article

C2 - 21854453

SN - 0902-4441

VL - 88

SP - 78

EP - 86

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 1

ER -

Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater